Long-Term Real-World Outcomes of Corneal Changes in Proliferative Diabetic Retinopathy: Panretinal Photocoagulation vs. Intravitreal Conbercept

Photodiagnosis Photodyn Ther. 2023 Dec:44:103765. doi: 10.1016/j.pdpdt.2023.103765. Epub 2023 Aug 23.

Abstract

Purpose: To compare long-term real-world outcomes of corneal thickness (CT) alterations in proliferative diabetic retinopathy (PDR) patients treated with panretinal photocoagulation (PRP) and intravitreal conbercept (IVC).

Methods: This retrospective study included 69 eyes of 69 patients with PDR (42 PRP and 27 IVC). Full corneal thickness (FCT), corneal epithelial thickness (CET) and corneal stromal thickness (CST) measured by anterior segment optical coherence tomography at baseline were compared between groups. These CT changes at last follow-up from baseline were also compared between groups and within each group.

Results: During a mean follow-up of more than two years, the IVC group demonstrated a significantly increased corneal thickness from baseline compared to the PRP group in some areas (PRP vs. IVC: FCT 0-2 mm: -0.59 ± 9.31 vs. 5.59 ± 9.23 μm, p = 0.009; CST 0-2 mm: -2.05 ± 8.79 vs. 3.48 ± 7.52 μm, p = 0.015; CST 2-5 mm: -1.78 ± 13.27 vs. 5.68 ± 14.53 μm, p = 0.046). In within-group comparisons, a significantly increased FCT from baseline was found in the 0-2 mm area in the IVC group (p = 0.004), but no significant change was observed in the PRP group (p = 0.691). For CET changes, a significantly increased CT was observed in the 0-2 mm, 2-5 mm and 5-7 mm areas in both groups respectively (all p < 0.05). Regarding CST, an increased CT was found in the 0-2 mm area in the IVC group (p = 0.037), while a decreased trend was observed in 0-2 mm and 2-5 mm areas in the PRP group (all p > 0.05).

Conclusion: When using PRP or IVC in the long-term management of PDR, CT changes should be considered. This may provide evidence for corneal protection during PDR treatment.

Keywords: Long-term; anterior segment optical coherence tomography; conbercept; corneal thickness; panretinal photocoagulation; proliferative diabetic retinopathy; real-world.

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use
  • Diabetes Mellitus*
  • Diabetic Retinopathy* / drug therapy
  • Diabetic Retinopathy* / surgery
  • Humans
  • Intravitreal Injections
  • Laser Coagulation / methods
  • Photochemotherapy* / methods
  • Photosensitizing Agents / therapeutic use
  • Ranibizumab / therapeutic use
  • Retrospective Studies
  • Tomography, Optical Coherence
  • Vascular Endothelial Growth Factor A

Substances

  • Ranibizumab
  • Angiogenesis Inhibitors
  • KH902 fusion protein
  • Vascular Endothelial Growth Factor A
  • Photosensitizing Agents